Advancing NIAID’s critical work
“We are honored to partner with NIAID and Metabolon in this effort to define how the human response to SARS-CoV-2 correlates to COVID severity and outcome” -Dr. Ofer Levy, Director of the Precision Vaccines Program (PVP) at Boston Children’s Hospital
Understanding the pathophysiology and immune response of infectious diseases is vital for discovering effective treatments. These case studies support several problem-oriented metabolomics applications to SARS-CoV-2 by identifying metabolomic changes during infection and predicting disease severity and need for effective intervention and efficacy.
When dealing with a pandemic like COVID-19, vaccine development and discovery of therapeutics are essential to improving outcomes. These case studies address the need for actionable insights for vaccine development that metabolomics provides through a comprehensive view driving operational and quality improvements and antibody production.
Understanding the effects of age, gender and comorbidities on susceptibility to COVID-19, response to treatment and outcomes like mortality are vital for improved outcomes. These case studies highlight how metabolomics guides effective intervention and efficacy.
Comprehensive metabolomic profiling can simultaneously inform on several biological processes relevant to infection, such as inflammatory and redox markers, energetics, microbiome contribution and xenobiotic impact. These insights can lead to predictive response signatures and therapy strategies. The following case studies demonstrate how metabolomics enhances understanding of viral activity, helps to predict viral treatment and supports informed decisions on vaccine development.